Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/29/2024 | Underperform → Hold | Jefferies | |
5/13/2024 | Mkt Perform → Outperform | Bernstein | |
5/7/2024 | Underperform → Neutral | Exane BNP Paribas | |
4/30/2024 | Sell → Neutral | UBS | |
4/30/2024 | Underweight → Neutral | JP Morgan | |
2/7/2024 | Outperform → Underperform | Exane BNP Paribas | |
7/12/2023 | Buy | Goldman | |
1/17/2023 | Neutral → Sell | UBS |
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)
Jefferies upgraded Philips from Underperform to Hold
Bernstein upgraded Philips from Mkt Perform to Outperform
Exane BNP Paribas upgraded Philips from Underperform to Neutral
November 12, 2024 Designed specifically for use in radiation oncology, new Spectral CT 7500 RT enables personalized radiation therapy planning to deliver better care for more cancer patients Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced a major advance in radiation oncology with 510(k) clearance from the US Food and Drug Administration (FDA) for its new detector-based spectral computed tomography (CT) radiotherapy solution. Philips Spectral CT 7500 RT marks the next step in personalized cancer care by integrating the unique tumor visualization and tissue characterization capabilities of spectral CT into cancer trea
October 28, 2024 Third-quarter highlights Group sales amounted to EUR 4.4 billion, with flat comparable sales growthIncome from operations was EUR 337 millionAdjusted EBITA margin increased by 160 basis points from 10.2% to 11.8% of salesOperating cashflow of EUR 192 million, with a free cashflow of EUR 22 millionComparable order intake decreased by 2%, due to decline in ChinaOutlook for full-year 2024 revised to reflect deteriorated demand in China: comparable sales growth within an updated range 0.5%-1.5%, Adjusted EBITA margin at around 11.5%, the upper end of current range; free cashflow at around EUR 0.9 billion, at lower end of current range Roy Jakobs, CEO of Royal Philips:
July 29, 2024 Second-quarter highlights Group sales amounted to EUR 4.5 billion, with comparable sales growth of 2%Comparable order intake increased by 9%Income from operations EUR 816 million, including EUR 538 million insurance income*)Adjusted EBITA margin increased to 11.1% of salesOperating cash inflow of EUR 89 million, with a free cash outflow of EUR 64 million Roy Jakobs, CEO of Royal Philips:"I am encouraged by our return to order intake growth this quarter, primarily driven by North America. Within a challenging macro environment we achieved strong margin improvement, supported by our productivity program, solid operational cashflow due to improved working capital m
January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the appointment of Jie Xue as Chief Business Leader Precision Diagnosis, and Özlem Fidanci as Chief of International Region, both effective January 1, 2025. Ms. Xue and Ms. Fidanci have joined Philips' Executive Committee and report directly to Roy Jakobs, CEO of Philips.Ms. Xue joins Philips from GE Healthcare to lead the Precision Diagnosis business that was temporarily led by Bert van Meurs, who will continue to lead Philips' Image Guided Therapy business. Ms. Xue and Mr. Van Meurs will be jointly responsible for the Diagnosis & Treatment segment. Ms. F
July 3, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of Philips' Executive Committee, reporting to Philips CEO Roy Jakobs. She succeeds Andy Ho, who has decided to retire after a long and successful career. Ms Liu and Mr Ho continue to work together to ensure a smooth handover. "Ling is a talented, trusted leader and I am delighted that she will join Philips' Executive Committee as the Chief Region Leader of Philips Greater China," said Roy Jakobs, CEO of Royal Philips. "Sh
May 7, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2024, including: The re-appointment of Chairman Feike Sijbesma and Peter Löscher as members of the Supervisory Board.The appointment of Benoît Ribadeau-Dumas as member of the Supervisory Board.The appointment of Charlotte Hanneman as member of the Board of Management, with effect from October 1, 2024.The discharge of the members of the Board of Management and members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2024 can be found below.
SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)
SC 13D/A - KONINKLIJKE PHILIPS NV (0000313216) (Subject)
SC 13D - KONINKLIJKE PHILIPS NV (0000313216) (Subject)
January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the appointment of Jie Xue as Chief Business Leader Precision Diagnosis, and Özlem Fidanci as Chief of International Region, both effective January 1, 2025. Ms. Xue and Ms. Fidanci have joined Philips' Executive Committee and report directly to Roy Jakobs, CEO of Philips.Ms. Xue joins Philips from GE Healthcare to lead the Precision Diagnosis business that was temporarily led by Bert van Meurs, who will continue to lead Philips' Image Guided Therapy business. Ms. Xue and Mr. Van Meurs will be jointly responsible for the Diagnosis & Treatment segment. Ms. F
To help ensure more families have access to educational resources they need for healthy birth outcomes, the Northeast Florida Healthy Start Coalition (NEFHSC), Baptist Health and Philips Avent (NYSE:PHG, AEX: PHIA)) have partnered to offer a one-year, no-cost subscription to the premium version of Philips' Pregnancy+. Pregnancy+, the number one pregnancy app worldwide, will be available to women and their families in Baker, Clay and Duval counties. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209267840/en/Philips Avent Pregnancy+ (Photo: Business Wire) "We want to do everything we can to improve the health and well-being of
December 3, 2024 Collaboration intends to leverage proprietary AI technology from Philips and Mayo Clinic to target breakthroughs in ease-of-use and efficiency to bring high-quality diagnostic MRI and better care to more patients with heart disease Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE:PHG, AEX: PHIA)) and Mayo Clinic today announced a research collaboration aimed at advancing MRI for cardiac applications. Through this investigation, Philips and Mayo Clinic will look to harness the power of AI and the expertise of Mayo Clinic physicians to increase operational efficiency by shortening complex MRI exams and improving workflow for radiologists. Ischemic heart di